McCrackin v. Rex Medical L.P. et al

On January 8, 2026, plaintiff John McCrackin filed a product liability action against Rex Medical L.P. and related entities in federal court in Pennsylvania. The case originated from an Option retrievable inferior vena cava filter manufactured by Rex Medical and implanted in McCrackin in 2017 to prevent pulmonary embolism. Years later, diagnostic imaging revealed the filter had fractured, with a metal strut migrating to his heart, causing pericardial effusion and necessitating emergency open‑heart surgery. McCrackin alleged the filter had a defective design prone to fracture, that Rex Medical failed to provide adequate warnings to physicians and patients, and that the company continued marketing the device despite knowledge of elevated failure rates. The lawsuit sought compensatory and punitive damages for severe physical pain, permanent impairment, and substantial medical costs. The case is part of a broader multidistrict litigation concerning IVC filter defects.

Following a bifurcated trial that concluded in May 2026, the jury returned a verdict in favor of McCrackin, finding Rex Medical liable for defective design and failure to warn. The jury awarded $6.2 million in compensatory damages and an additional $15 million in punitive damages, citing reckless disregard for patient safety. The court entered judgment accordingly, and the defendants have filed a notice of appeal.

Whether the Option IVC filter’s design was unreasonably dangerous and caused McCrackin’s injuries; whether Rex Medical fulfilled its duty to warn of fracture and migration risks; and the apportionment of liability among defendants.

The verdict intensified scrutiny of retrievable IVC filter safety, prompting consumer advocacy groups to demand stricter post‑market surveillance. It influenced settlement negotiations in hundreds of similar pending cases and reinforced calls for the FDA to mandate more rigorous long‑term safety studies for permanently implanted medical devices.